CNSX:MYCO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Mydecine Innovations Group Inc., a life sciences company, develops, markets, and distributes cannabidiol and psilocybin products in North America. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Mydecine Innovations Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MYCO is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: MYCO's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of Canadian stocks.


Market Performance


7 Day Return

33.3%

MYCO

9.2%

CA Pharmaceuticals

2.8%

CA Market


1 Year Return

-5.9%

MYCO

14.8%

CA Pharmaceuticals

-0.3%

CA Market

Return vs Industry: MYCO underperformed the Canadian Pharmaceuticals industry which returned 13.1% over the past year.

Return vs Market: MYCO underperformed the Canadian Market which returned -0.5% over the past year.


Shareholder returns

MYCOIndustryMarket
7 Day33.3%9.2%2.8%
30 Day48.8%30.1%10.0%
90 Day-40.7%29.9%5.7%
1 Year-5.9%-5.9%14.8%14.8%3.3%-0.3%
3 Year-92.9%-92.9%-31.8%-32.9%12.2%1.3%
5 Year-87.1%-87.1%268.2%265.3%49.1%26.2%

Long-Term Price Volatility Vs. Market

How volatile is Mydecine Innovations Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mydecine Innovations Group undervalued compared to its fair value and its price relative to the market?

3.07x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MYCO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MYCO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MYCO is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.

PE vs Market: MYCO is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYCO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYCO is overvalued based on its PB Ratio (3.1x) compared to the CA Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Mydecine Innovations Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

60.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mydecine Innovations Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Mydecine Innovations Group performed over the past 5 years?

-8.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MYCO is currently unprofitable.

Growing Profit Margin: MYCO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MYCO is unprofitable, and losses have increased over the past 5 years at a rate of 8.4% per year.

Accelerating Growth: Unable to compare MYCO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYCO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-45%).


Return on Equity

High ROE: MYCO has a negative Return on Equity (-34.82%), as it is currently unprofitable.


Next Steps

Financial Health

How is Mydecine Innovations Group's financial position?


Financial Position Analysis

Short Term Liabilities: MYCO's short term assets (CA$3.4M) exceed its short term liabilities (CA$564.6K).

Long Term Liabilities: MYCO has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: MYCO is debt free.

Reducing Debt: MYCO has no debt compared to 5 years ago when its debt to equity ratio was 211.1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MYCO has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: MYCO is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Mydecine Innovations Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MYCO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MYCO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYCO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYCO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYCO's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.4yrs

Average board tenure


CEO

David Bartch

2.33yrs

Tenure

CA$237,537

Compensation

Mr. David Joshua Bartch is Co-Founder of Mydecine Innovations Group Inc. and serves as its President, Chief Executive Officer and Interim Chief Financial Officer since July 30, 2018 and has been its Direct...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD182.49K) is about average for companies of similar size in the Canadian market ($USD166.12K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
David Bartch
Co-Founder2.33yrsCA$237.54k18.31%
CA$ 8.4m
Michael Connolly
Director & CCO2.33yrsCA$145.80k1.26%
CA$ 579.8k
Robert Roscow
Co-Founderno datano datano data
Damon Michaels
COO, Co-Founder & Director0.25yrno datano data
Erik Knutson
Independent Director2.42yrsno datano data
Anton Gomez-Escolar
Member of Scientific Advisory Board0.42yrno datano data
Vince Polito
Member of Scientific Advisory Board0.42yrno datano data
Denton Hoyer
Member of Scientific Advisory Board0.25yrno datano data
Malireddy Reddy
Member of Scientific Advisory Board0.25yrno datano data
Aubrey Oliver
Member of Scientific Advisory Board0.25yrno datano data
Ruth Lanius
Member of Scientific Advisory Boardno datano datano data
Gary Wynn
Member of Scientific Advisory Boardno datano datano data

0.4yrs

Average Tenure

Experienced Board: MYCO's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 398.6%.


Top Shareholders

Company Information

Mydecine Innovations Group Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mydecine Innovations Group Inc.
  • Ticker: MYCO
  • Exchange: CNSX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$45.848m
  • Shares outstanding: 166.72m
  • Website: https://www.mydecine.com

Location

  • Mydecine Innovations Group Inc.
  • 789 West Pender Street
  • Suite 810
  • Vancouver
  • British Columbia
  • V6C 1H2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYCOCNSX (Canadian National Stock Exchange)YesCommon SharesCACADMar 2015
MYCO.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2015
0NFADB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2015

Biography

Mydecine Innovations Group Inc., a life sciences company, develops, markets, and distributes cannabidiol and psilocybin products in North America. It develops natural health products, including psychedelic...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 00:33
End of Day Share Price2020/11/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.